

Fig. 2. Preparation of C-CPEs. (A) Schematic structure of C-CPEs. Van Itallie et al. determined the 3-dimensional structure of C-CPE194 containing nine β -sheets and one α -helix [26]. Based on the structural information, we designed five N-terminal truncated C-CPE184 derivatives. (B) CBB staining. C-CPEs were prepared and then purified by affinity chromatography. Lane 1, a maker for molecular weight; lane 2, C-CPE184; lane 3, C-CPE194; lane 4, C-CPE205; lane 5, C-CPE212; lane 6, C-CPE219; lane 7, C-CPE224.

Table 3
Binding kinetics of C-CPEs to claudin-4.

Derivatives	k_a (1/Ms)	k_d (1/s)	K_D
C-CPE184	5.96×10^5	2.55×10^{-4}	429 pM
C-CPE194	7.13×10^5	3.24×10^{-4}	455 pM
C-CPE205	7.67×10^5	2.87×10^{-4}	374 pM

BV-adsorbed immunoplates, C-CPE194 and C-CPE205 bound to claudin-4-displaying BV but not mock BV or claudin-1-displaying BV (Fig. 3A). We performed SPR analysis to compare the affinities of C-CPEs to claudin-4. Claudin-4 proteins were fixed on the sensor chip, and C-CPEs were injected. Then, we measured the interaction between claudin-4 and C-CPEs. As shown in Fig. 3B and Table 3, C-CPE184, C-CPE194 and C-CPE205 had almost the same affinity to claudin-4 with K_D values of 429, 455 and 374 pM, respectively. The association and dissociation rates of C-CPE194 and C-CPE205 were also similar to those of C-CPE184. C-CPE184, C-CPE194 and C-CPE205 showed similar TJ-modulating activities in Caco-2 monolayer cells; their EC_{50} values were 0.49, 0.57 and 0.51 μ g/ml, respectively (Fig. 4A and Table 4). We performed in situ loop assays to examine the jejunal absorption of FD-4 by C-CPEs. C-CPE194 and C-CPE205 enhanced the jejunal absorption of FD-4 similar to C-CPE184 at 0.2 mg/ml (Fig. 4B–D). Treatment with C-CPE194 or C-CPE205 at 1.0 mg/ml yielded a greater and earlier absorption of FD-4 than treatment at 0.2 mg/ml (Fig. 4B, C). We could not test 1.0 mg/ml of C-CPE184 due to its low solubility.




Fig. 3. Interaction of C-CPEs with claudin. (A) ELISA. The immunoplate was coated with wild-type BV (Wild-BV), claudin-1-displaying BV (CL1-BV) or claudin-4-displaying BV (CL4-BV), and then C-CPEs were added to the well. C-CPEs bound to BVs were detected by the addition of anti-his tag antibody and a labeled secondary antibody. Data are means \pm SD ($n = 3$). (B) SPR assay. Claudin-4 was immobilized on a CM5 sensor chip by the amine-coupling method. C-CPEs were injected sequentially at concentrations of 1.25, 2.5, 5, 10 and 20 nM. The association phase was monitored for 120 s at a flow rate of 10 μ l/min, and the dissociation phase was followed for 600 s at the same flow rate. The maximum values of response (Rmax) for all curves were compensated to 100 RU.

3.4. Jejunal and pulmonary absorption of hPTH(1-34) by co-treatment with C-CPE194

C-CPE194 enhanced the jejunal absorption of FD-4 to a similar extent as C-CPE184 and C-CPE205; C-CPE194 was also 30- and 3-fold more soluble than C-CPE184 and C-CPE205, respectively. C-CPE194 enhanced the jejunal absorption of hPTH(1-34) at 0.2 and 4.0 mg/ml (Fig. 5A). The AUC values were increased 11.0- and 18.4-fold as compared to the vehicle-treated group (Fig. 5B), and the C_{max} and BA of the jejunal absorption of hPTH(1-34) were also increased by C-CPE194 (Table 5). Additionally, the pulmonary absorption of hPTH(1-34) was enhanced by C-CPE194 (AUC = 3080.0 ± 1994.3 ng·min/ml in vehicle-treated group, AUC = $13,397.7 \pm 5830.1$ ng·min/ml in C-CPE194 (0.8 mg/ml)-treated group) (Fig. 5C, D). The C_{max} and BA of hPTH(1-34) were also increased by C-CPE194 (Table 5).

4. Discussion

Biologics are generally hydrophilic and poorly absorbed by the mucosa; therefore, many biologics are administered via injection. The development of a delivery system to allow biologics to pass across the epithelial barrier in mucosa is a pivotal issue for pharmaceutical therapy with biologics, since mucosal administration is needle-free, non-invasive, convenient and comfortable for patients [30,31]. We previously found that C-CPE184 enhanced jejunal absorption of dextran with a molecular mass of <10 kDa through its modulation of the claudin-4 barrier [21]. In the present study, we investigated the effect of a claudin-4 modulator on the mucosal absorption of a biologic, hPTH(1-34), and we found that a claudin-4 modulator is also a potent jejunal, nasal and pulmonary absorption enhancer of this biologic.

CPE is a 35-kDa polypeptide consisting of 319 amino acids [32]. The functional domain of CPE is divided into an N-terminal toxic domain and a C-terminal receptor-binding domain [33]. The receptor-binding fragments of CPE correspond to amino acids 169–319, 171–319, 184–319, 194–319 and 290–319 [20,26,33–35]. Among these fragments, only C-CPE184 and C-CPE194 have been




Fig. 4. Modulation of the TJ-barrier by C-CPEs. (A) Caco-2 cells were seeded on a BioCoat™. When TJ-barriers were developed and the cell sheets reached a plateau in their TEER value, C-CPEs were added to the wells from the basal side at the indicated concentration. After 18 h, the TEER was measured. The Δ TEER was calculated as the ratio to reduced TEER values at 0 and 100 μ g/ml of C-CPE184 as 0% and 100%, respectively. Data are mean \pm SD ($n = 3$). (B–D) Jejunal absorption of FD-4. Jejunum were treated with FD-4 and C-CPEs at the indicated concentration. Time-course changes in plasma FD-4 levels (B, C) and AUC from 0 to 6 h (D). Data are means \pm SE ($n = 4$ –9). *Significantly different from the vehicle-treated group ($p < 0.05$).

proven to bind to claudin-4 [10,26], and a mucosal-absorption-enhancing effect was proven only for C-CPE184 [21]. The claudin-4 modulator C-CPE184 is a 400-fold more potent jejunal absorption enhancer of dextran as compared to a clinically used absorption enhancer, sodium caprate [21]. However, the low solubility of C-CPE184 (<0.3 mg/ml in PBS) has limited its applicability. This low solubility may result in the slow onset of TJ opening due to limiting the access of C-CPE184 to claudin. Last year, Van Itallie et al. made a breakthrough by truncating the N-terminal of C-CPE184 by 10 amino acids to yield C-CPE194 [26]. They found that C-CPE194 has affinity to claudin-4 and high solubility (>10 mg/ml); moreover, they determined the 3-dimensional structure of C-CPE194, which contains nine β -sheets and one α -helix, and they suggested that the intervening surface loop spanning region 304–312 (located between the β 8 and β 9 sheets) may be a claudin-binding domain. Based on the structural data for C-CPE194, we prepared five N-terminal-truncated C-CPE184 derivatives: C-CPE194, C-CPE205, C-

CPE212 (without the β 1 sheet), C-CPE219 (without the β 1 sheet and α helix), and C-CPE224 (without the β 1 sheet and α helix). C-CPEs lacking the β 1 sheet are soluble in PBS containing 2 M Urea but insoluble in PBS. C-CPE184, C-CPE194 and C-CPE205 have almost the same kinetics parameters for binding to claudin-4 and the same TJ-barrier modulating activity (Table 3, Fig. 4A). Thus, the β 1 sheet appears to be critical for maintaining the structure of C-CPE, and the N-terminal region corresponding to amino acids 184–204 may not be involved in claudin-4 binding or TJ-barrier modulation.

Biologics must escape degradation by mucosal enzymes to be absorbed by the mucosa. C-CPE184 (0.2 mg/ml) did not enhance jejunal or pulmonary absorption of hPTH(1–34). However, when hPTH(1–34) was administered 4 h after treatment with C-CPE184, jejunal, pulmonary and nasal absorption was enhanced. Thus, hPTH(1–34) may be degraded in the jejunal and pulmonary mucosa before the enhancement of its absorption by co-administered C-CPE184. Indeed, another claudin-4 modulator, C-CPE194, which is 30-fold more soluble than C-CPE184, significantly enhanced the jejunal and pulmonary absorption of hPTH(1–34). These findings indicate that modulation of claudin-4 may be a potent strategy for mucosal-absorption enhancement of biologics.

Meanwhile, a critical issue in the clinical application of the claudin-4 modulator as a mucosal-absorption enhancer is its safety. Problems with the safety of a claudin-4 modulator include the safety of a claudin-4 modulator in itself and the safety of the modulation of claudin-4, i.e., entry of unwanted substances by the

Table 4
TJ-modulating activities of C-CPEs in Caco-2 cells.

Derivatives	EC50 values ^a
C-CPE184	0.49 μ g/ml
C-CPE194	0.57 μ g/ml
C-CPE205	0.51 μ g/ml

^a The concentration of C-CPEs at which a 50% decrease in TEER value was observed in Fig. 4A.




Fig. 5. Mucosal absorption of hPTH(1-34) by a claudin-4 modulator. (A, B) Jejunal absorption of hPTH(1-34). Rat jejunum was treated with hPTH(1-34) (100 µg) and C-CPE194 at the indicated doses. Time-course changes in plasma hPTH(1-34) (A) and AUC from 0 to 120 min (B) were analyzed. (C, D) Pulmonary absorption of hPTH(1-34). hPTH(1-34) (150 µg) and C-CPE194 at the indicated doses were pulmonary administered, and time-course changes in plasma hPTH(1-34) concentration (C) and AUC from 0 to 120 min (D) were analyzed. Data are mean ± SE (n = 3). *Significantly different from the vehicle-treated group (p < 0.05).

opening of TJs. As mentioned above, C-CPEs are the only claudin-4 modulator. C-CPEs are polypeptide fragments of CPE consisting of more than 120 amino acids, and C-CPEs themselves may have antigenicity. Claudin-4 modulator significantly enhanced jejunal absorption of dextran with a molecular mass of less than 10 kDa [21], and C-CPEs (>14.2 kDa) may not be absorbed by the modulation of claudin-4. Moreover, *C. perfringens* are indigenous bacterium, and immunological tolerance may be induced. Thus, the antigenicity of C-CPE might be partly negligible. Because absorption enhancers would be used as an additive in drugs, they would be repeatedly administered. To avoid the risk of antigenicity, the development of a chemical compound-type or a 30–40 mer peptide-type of claudin modulator is needed. The determination of the 3-dimensional structure of claudin is also important for the theoretical development of promising claudin modulators. Ling et al. prepared a 12-mer peptide-type claudin-4 binder which did

not modulate TJs [36], and Van Itallie et al. determined the structure of C-CPE [26]. A peptide-type claudin modulator will be developed in the near future.

The other safety issue is the possible influx of unwanted substances that could be caused by the opening of TJs. C-CPE has demonstrated no damages to mucosal epithelial tissue in rat intestine [21]. Treatment of cells with C-CPE decreased the level of intracellular claudin-4 proteins paralleled by a disruption of the TJ-barrier [10]. Claudin contains the clathrin-sorting signal in its C-terminal intracellular domain, and claudin was often internalized [37,38]. Taken together, these results indicate that C-CPEs may disrupt the TJ-barrier, allowing the movement of solutes through the paracellular route. Do claudin modulators reversibly modulate the TJ-barrier and specifically regulate the movement of solutes? Disruption of the TJ-barrier by C-CPE is reversible, and the TJ-barrier gradually recovered after the removal of C-CPE [10]. The

Table 5
Parameters of mucosal absorption of hPTH(1-34) in C-CPE 194-treated rats.

C-CPE194 (mg/ml)	Jejunum		C-CPE194 (mg/ml)	Pulmonary	
	Cmax (ng/ml)	BA (%) ^a		Cmax (ng/ml)	BA (%)
0	0.3 ± 0.0	0.1 ± 0.0	0	62.3 ± 32.8	26.5 ± 17.4
0.2	1.2 ± 0.4 [*]	0.8 ± 0.2 ^{**}	0.2	78.7 ± 66.1	34.1 ± 21.6
4.0	2.8 ± 0.2 [*]	1.3 ± 0.3 ^{**}	0.8	205.2 ± 79.4 [*]	100.6 ± 39.3 [*]

^a BA (%) = (AUC/Dose)/(AUC iv/Dose iv).
Data are mean ± SE.
^{*}p < 0.05, ^{**}p < 0.01 as compared to the vehicle-treated group.

quick recovery of TJ-barriers will need to be facilitated. One approach is the development of a quickly reversible claudin modulator. Another approach is the development of a claudin inducer for the combination of a claudin modulator and inducer. Another approach is the reduction of unwanted transport using the properties of claudins. Claudin comprises a multigene family consisting of 24 members. Claudin forms paired TJ strands by polymerization in a homomeric and heteromeric manner, and the claudin strands interact in a homotypic and heterotypic manner between adjacent cells [39,40]. TJ-barrier properties are believed to be determined by the combination and mixing ratios of claudin species [41]. Interestingly, the diversity of claudin may contribute to the regulation of specific solute movement through the paracellular route [17]. The expression profiles of claudin in mucosal epithelium exhibit heterogeneity [13–15,42]. The development of claudin modulators with solute and tissue specificity will reduce the non-specific influx of solutes caused by the modulation of TJs.


In summary, we found that claudin-4 modulator enhanced the jejunal, pulmonary and nasal absorption of a peptide drug. This report is the first to indicate that a claudin-4 modulator may be a mucosal-absorption enhancer of biologics.

Acknowledgments

We thank M. Hoshino (Asubio Pharma), N. Kumagai (Asubio Pharma), K. Takashiba (Asubio Pharma), R. Okude (Osaka University) and Y. Nakano (GE Healthcare, Japan) for their excellent technical assistance. We also thank Drs Y. Horiguchi (Osaka University) and M. Furuse (Kobe University) for providing us C-CPE cDNA and claudin cDNA, respectively. This work was supported by a Grant-in-Aid for Scientific Research (21689006) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, by a Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan and by a grant from Kansai Biomedical Cluster project in Saito, which is promoted by the Knowledge Cluster Initiative of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References

- [1] Powell DW. Barrier function of epithelia. *Am J Physiol* 1981;241:G275–88.
- [2] Engel RH, Riggi SJ. Effect of sulfated and sulfonated surfactants on the intestinal absorption of heparin. *Proc Soc Exp Biol Med* 1969;130:879–84.
- [3] Tidball CS, Lipman RI. Enhancement of jejunal absorption of heparinoid by sodium ethylenediaminetetraacetate in the dog. *Proc Soc Exp Biol Med* 1962;111:713–5.
- [4] Aungst BJ. Intestinal permeation enhancers. *J Pharm Sci* 2000;89:429–42.
- [5] Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. *Biochim Biophys Acta* 2009;1788:892–910.
- [6] Matsuhisa K, Kondoh M, Takahashi A, Yagi K. Tight junction modulator and drug delivery. *Expert Opin Drug Deliv* 2009;6:509–15.
- [7] Kondoh M, Yoshida T, Kakutani H, Yagi K. Targeting tight junction proteins-significance for drug development. *Drug Discov Today* 2008;13:180–6.
- [8] Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, et al. Occludin: a novel integral membrane protein localizing at tight junctions. *J Cell Biol* 1993;123:1777–88.
- [9] Furuse M, Fujita K, Hiiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. *J Cell Biol* 1998;141:1539–50.
- [10] Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, et al. *Clostridium perfringens* enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. *J Cell Biol* 1999;147:195–204.
- [11] Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. *J Cell Biol* 2002;156:1099–111.
- [12] Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. *J Cell Biol* 2003;161:653–60.
- [13] Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. *Gastroenterology* 2001;120:411–22.
- [14] Takano K, Kojima T, Go M, Murata M, Ichimiya S, Himi T, et al. HLA-DR- and CD11c-positive dendritic cells penetrate beyond well-developed epithelial tight junctions in human nasal mucosa of allergic rhinitis. *J Histochem Cytochem* 2005;53:611–9.
- [15] Wang F, Daugherty B, Keise LL, Wei Z, Foley JP, Savani RC, et al. Heterogeneity of claudin expression by alveolar epithelial cells. *Am J Respir Cell Mol Biol* 2003;29:62–70.
- [16] Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE. Structure and function of claudins. *Biochim Biophys Acta* 2008;1778:631–45.
- [17] Krause G, Winkler L, Pielh C, Blasig I, Piontek J, Muller SL. Structure and function of extracellular claudin domains. *Ann N Y Acad Sci* 2009;1165:34–43.
- [18] McClane BA, Hanna PC, Wnek AP. *Clostridium perfringens* enterotoxin. *Microb Pathog* 1988;4:317–23.
- [19] Fujita K, Katahira J, Horiguchi Y, Sonoda N, Furuse M, Tsukita S. *Clostridium perfringens* enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. *FEBS Lett* 2000;476:258–61.
- [20] Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Molecular cloning and functional characterization of the receptor for *Clostridium perfringens* enterotoxin. *J Cell Biol* 1997;136:1239–47.
- [21] Kondoh M, Masuyama A, Takahashi A, Asano N, Mizuguchi H, Koizumi N, et al. A novel strategy for the enhancement of drug absorption using a claudin modulator. *Mol Pharmacol* 2005;67:749–56.
- [22] Wray C, Mao Y, Pan J, Chandrasena A, Piasta F, Frank JA. Claudin-4 augments alveolar epithelial barrier function and is induced in acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2009;297:L219–27.
- [23] Suzuki Y, Yabuta M, Ohsuye K. High-level production of recombinant human parathyroid hormone 1–34. *Appl Environ Microbiol* 1998;64:526–9.
- [24] Saeki R, Kondoh M, Kakutani H, Tsunoda SI, Mochizuki Y, Hamakubo T, et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. *Mol Pharmacol* 2009;76:918–26.
- [25] Mitic LL, Unger VM, Anderson JM. Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin-4. *Protein Sci* 2003;12:218–27.
- [26] Van Itallie CM, Betts L, Smedley 3rd JG, McClane BA, Anderson JM. Structure of the claudin-binding domain of *Clostridium perfringens* enterotoxin. *J Biol Chem* 2008;283:268–74.
- [27] Karlsson R, Katsamba PS, Nordin H, Pol E, Myszkla DG. Analyzing a kinetic titration series using affinity biosensors. *Anal Biochem* 2006;349:136–47.
- [28] Myszkla DG. Improving biosensor analysis. *J Mol Recognit* 1999;12:279–84.
- [29] Takahashi A, Komiya E, Kakutani H, Yoshida T, Fujii M, Horiguchi Y, et al. Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of *Clostridium perfringens* enterotoxin, by site-directed mutagenesis. *Biochem Pharmacol* 2008;75:1639–48.
- [30] Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. *Crit Rev Ther Drug Carrier Syst* 1996;13:85–184.
- [31] Song Y, Wang Y, Thakur R, Meidan VM, Michniak B. Mucosal drug delivery: membranes, methodologies, and applications. *Crit Rev Ther Drug Carrier Syst* 2004;21:195–256.
- [32] Czezulini JR, Hanna PC, McClane BA. Cloning, nucleotide sequencing, and expression of the *Clostridium perfringens* enterotoxin gene in *Escherichia coli*. *Infect Immun* 1993;61:3429–39.
- [33] Hanna PC, Wieckowski EU, Mietzner TA, McClane BA. Mapping of functional regions of *Clostridium perfringens* type A enterotoxin. *Infect Immun* 1992;60:2110–4.
- [34] Hanna PC, Mietzner TA, Schoolnik GK, McClane BA. Localization of the receptor-binding region of *Clostridium perfringens* enterotoxin utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids define a functional binding region. *J Biol Chem* 1991;266:11037–43.
- [35] Kokai-Kun JF, McClane BA. Deletion analysis of the *Clostridium perfringens* enterotoxin. *Infect Immun* 1997;65:1014–22.
- [36] Ling J, Liao H, Clark R, Wong MS, Lo DD. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. *J Biol Chem* 2008;283:30585–9.
- [37] Ivanov AI, Nusrat A, Parkos CA. Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment. *Mol Biol Cell* 2004;15:176–88.
- [38] Matsuda M, Kubo A, Furuse M, Tsukita S. A peculiar internalization of claudins, tight junction-specific adhesion molecules, during the intercellular movement of epithelial cells. *J Cell Sci* 2004;117:1247–57.
- [39] Furuse M, Furuse K, Sasaki H, Tsukita S. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. *J Cell Biol* 2001;153:263–72.
- [40] Furuse M, Sasaki H, Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. *J Cell Biol* 1999;147:891–903.
- [41] Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. *Trends Cell Biol* 2006;16:181–8.
- [42] Coyne CB, Gambling TM, Boucher RC, Carson JL, Johnson LG. Role of claudin interactions in airway tight junctional permeability. *Am J Physiol Lung Cell Mol Physiol* 2003;285:L1166–78.



Prevention of hepatic ischemia–reperfusion injury by pre-administration of catalase-expressing adenovirus vectors

Masahiro Ushitora^{a,b}, Fuminori Sakurai^{a,*}, Tomoko Yamaguchi^{a,c}, Shin-ichiro Nakamura^d, Masuo Kondoh^b, Kiyohito Yagi^b, Kenji Kawabata^a, Hiroyuki Mizuguchi^{a,c,*}

^a Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, Osaka, Japan

^b Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

^c Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

^d Research Center of Animal Life Science, Shiga University of Medical Science, Otsu-City, Shiga, Japan

ARTICLE INFO

Article history:

Received 17 August 2009

Accepted 25 November 2009

Available online 29 November 2009

Keywords:

Adenovirus vector
Reactive oxygen
Ischemia/reperfusion
Liver
Catalase
Hepatectomy

ABSTRACT

Liver ischemia/reperfusion (I/R) injury, which is mainly caused by the generation of reactive oxygen species (ROS) during the reperfusion, remains an important clinical problem associated with liver transplantation and major liver surgery. Therefore, ROS should be detoxified to prevent hepatic I/R-induced injury. Delivery of antioxidant genes into liver is considered to be promising for prevention of hepatic I/R injury; however, therapeutic effects of antioxidant gene transfer to the liver have not been fully examined. The aim of this study was to examine whether adenovirus (Ad) vector-mediated catalase gene transfer in the liver is an effective approach for scavenging ROS and preventing hepatic I/R injury. Intravenous administration of Ad vectors expressing catalase, which is an antioxidant enzyme scavenging H₂O₂, resulted in a significant increase in catalase activity in the liver. Pre-injection of catalase-expressing Ad vectors dramatically prevented I/R-induced elevation in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and hepatic necrosis. The livers were also protected in another liver injury model, CCl₄-induced liver injury, by catalase-expressing Ad vectors. Furthermore, the survival rates of mice subjected to both partial hepatectomy and I/R treatment were improved by pre-injection of catalase-expressing Ad vectors. On the other hand, control Ad vectors expressing β-galactosidase did not show any significant preventive effects in the liver on the models of I/R-induced or CCl₄-induced hepatic injury described above. These results indicate that hepatic delivery of the catalase gene by Ad vectors is a promising approach for the prevention of oxidative stress-induced liver injury.

Crown Copyright © 2009 Published by Elsevier B.V. All rights reserved.

1. Introduction

Hepatic ischemia/reperfusion (I/R) injury occurs in a variety of clinical settings, such as in liver transplantation, hepatic failure after shock, and liver surgery, and results in severe damages that substantially contribute to the morbidity and mortality of such cases [1–3]. Hepatic I/R injury is caused by reactive oxygen species (ROS), including superoxide anion, hydrogen oxide, and hydroxyl radical, which are generated by reperfusion of the ischemic tissue. ROS induce lipid peroxidation and damages to proteins and nucleic acids, leading to parenchymal cell dysfunction and necrosis, increased vascular

permeability, and inflammatory cell infiltration [4]. Therefore, ROS should be detoxified to prevent hepatic I/R injury.

In previous animal studies, antioxidative enzyme catalase and superoxide dismutase (SOD) were systemically administered to neutralize ROS and prevent I/R-induced hepatic injury. Although catalase and SOD are endogenously expressed in the cells, the expression levels of these enzymes are insufficient to prevent I/R injury. Administration of antioxidant enzymes exhibited therapeutic effects on ROS-induced diseases, including I/R-induced hepatic injury, in several studies [5–8]; however, these enzymes are known to be rapidly eliminated from the circulation following systemic administration, which limits their therapeutic potential, [9,10] although chemical modification of antioxidant enzymes has been carried out to enhance their plasma half-lives and tissue accessibility [5,6,9]. In addition, systemically administered antioxidant enzymes might be degraded in the endosomes/lysosomes because they are internalized into the cells via the endocytosis pathway.

The delivery of therapeutic genes encoding antioxidant enzymes into the liver is considered to be a promising strategy to overcome these problems. Previous studies have demonstrated that ROS-mediated injury was efficiently prevented by over-expression of antioxidant

* Corresponding authors. Sakurai is to be contacted at Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, 5-6-7 Saito Asagi, Ibaraki, Osaka, 567-0085, Japan. Tel.: +81 72 641 9815; fax: +81 72 641 9816. Mizuguchi, Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. Tel./fax: +81 6 6879 8185.

E-mail addresses: sakurai@nibio.go.jp (F. Sakurai), mizuguch@phs.osaka-u.ac.jp (H. Mizuguchi).

enzymes in various tissues, including the artery, pancreatic islets, and brain [11–13]. A variety of types of gene delivery vehicles have been employed for delivery of antioxidant genes so far, and replication-incompetent adenovirus (Ad) vectors have several advantages over other vehicles to deliver antioxidant genes to the liver. First, Ad vectors have high tropism to livers. A more than 10^3 -fold higher transgene expression is found in the liver, compared with other organs, following systemic administration [14–16]. Second, non-dividing cells are efficiently transduced with Ad vectors. Hepatocytes do not actively divide under normal conditions. Non-viral gene delivery vehicles have been used for prevention of hepatic I/R injury in previous studies [17,18]; however, non-viral gene delivery vehicles mediate inefficient transfection in non-dividing cells. Third, the Ad vector genome is not integrated into the host genome, indicating that transduction with Ad vectors is unlikely to induce insertional mutagenesis in hepatocytes. Fourth, Ad vector-mediated gene expression in liver persists for 1–2 weeks, [19,20] in contrast, rapid reduction in plasmid DNA-mediated transgene expression in organs is found after injection of non-viral gene delivery vehicles [21,22]. In spite of these advantages of Ad vectors, the ability of Ad vectors expressing antioxidant enzymes to prevent hepatic I/R injury has not been fully examined probably because Ad vectors are generally considered more toxic than non-viral gene delivery vehicles; however, our group demonstrated that intravenous administration of Ad vectors induces less amounts of inflammatory cytokines than cationic lipid/plasmid DNA complexes [23]. In addition, fiber-modified Ad vectors carrying a stretch of lysine residues in the C-terminus of a fiber knob have been demonstrated to poorly activate innate immune responses after systemic injection, compared with conventional Ad vectors [24]. These results suggest that Ad vectors, including fiber-modified Ad vectors, would be suitable for prevention of I/R injury by delivering antioxidant genes to livers.

Among antioxidant enzymes, SOD is often used for detoxifying ROS in previous studies [8,17,25,26]. SOD catabolizes superoxide anion to H_2O_2 ; however, H_2O_2 is converted to hydroxyl radicals, which are extremely reactive and more toxic than other ROS. H_2O_2 should be removed to effectively reduce I/R injury. Another antioxidant enzyme, catalase, prevents the generation of hydroxyl radicals by catabolizing H_2O_2 to H_2O and O_2 , suggesting that catalase is promising for prevention of I/R injury. However, there are few studies reporting therapeutic effects of catalase gene delivery on I/R injury [17,27].

In the present study, catalase-expressing Ad vectors were intravenously pre-administered to prevent I/R-induced hepatic injury. Pre-injection of catalase-expressing Ad vectors successfully prevented not only I/R-induced hepatic injury but also CCl_4 -induced liver damages. Furthermore, mice receiving pre-injection of catalase-expressing Ad vectors showed improved survival rates after partial hepatectomy followed by hepatic I/R.

2. Materials and methods

2.1. Cells

A549 (a human lung adenocarcinoma epithelial cell line), HepG2 (a human hepatocellular liver carcinoma cell line), and 293 (a human embryonic kidney cell line) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum under 5% CO_2 at 37 °C.

2.2. Ad vectors

Ad vectors were constructed by means of an improved *in vitro* ligation method [28–30]. Briefly, the LacZ gene, which is derived from pCMV β (Marker Gene, Inc., Eugene, OR) and the catalase gene, which is derived from pZEOSV2-CAT (a kind gift from Dr. J. Andres Melendez, Albany Medical College, Albany, NY) [31,32] were inserted into pHMCA5, [33] creating pHMCA5-LacZ and pHMCA5-CAT, respectively.

pHMCA5-LacZ and pHMCA5-CAT were then digested with I-CeuI and PI-SceI, and ligated with I-CeuI/PI-SceI-digested pAdHM4 [28], resulting in pAdHM4-LacZ and pAdHM4-CAT, respectively. To generate the viruses, PacI-digested Ad vector plasmids were transfected into 293 cells plated in a 60-mm dish with SuperFect (Qiagen, Inc., Valencia, CA) according to the manufacturer's instructions. The viruses were prepared by the standard method, then purified with $CsCl_2$ gradient centrifugation, dialyzed with a solution containing 10 mM Tris (pH7.5), 1 mM $MgCl_2$, and 10% glycerol, and stored in aliquots at -80 °C. The determinations of infectious titers and virus particle (VP) titers were accomplished using 293 cells and an Adeno-X rapid titer kit (Clontech, Mountain View, CA) and the method of Maizel et al. [34], respectively. Catalase-, or β -galactosidase-expressing fiber-modified Ad vectors carrying a stretch of lysine residues (K7 (KKKKKKK) peptide) in the C-terminus of a fiber knob, AdK7-CAT and AdK7-LacZ, respectively, were similarly prepared using pAdHM41K7 [35]. The ratios of the biological-to-particle titer were 1:20, 1:31, 1:45, and 1:39 for Ad-LacZ, AdK7-LacZ, Ad-CAT, and AdK7-CAT, respectively.

2.3. Western blot analysis for catalase expression

A549 cells were transduced with Ad vectors at 3000 VP/cell for 2 h. Forty-eight hours later, cells were harvested and lysed with lysis buffer (20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1% Triton X-100, 10% glycerol) containing protease inhibitor cocktail (Sigma Chemical, St. Louis, MO). Equal quantities of protein (5 μ g), as determined by a protein assay (Bio-Rad, Hercules, CA), were subjected to sodium dodecyl sulfate/12.5% polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride membrane (Millipore, Bedford, MA). After blocking nonspecific binding, the membrane was incubated with anti-catalase antibody (diluted 1/8000; Calbiochem, San Diego, CA) at room temperature for 3 h, followed by reaction with horse radish peroxidase (HRP)-conjugated anti-rabbit IgG (diluted 1/3000; Cell Signaling Technology, Beverly, MA) at room temperature for 1 h. The band was visualized by ECL Plus Western blotting detection reagents (Amersham Bioscience, Piscataway, NJ), and the signals were read using an LAS-3000 imaging system (Fujifilm, Tokyo, Japan). For detection of the internal control, a polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase antibody (diluted 1/5000; Trevigen, Gaithersburg, MD) and an HRP-conjugated anti-rabbit IgG were used.

2.4. *In vitro* protective effect of catalase-expressing Ad vectors on ROS-induced cell damage

HepG2 cells (5000 cells/well) were seeded onto a 96-well plate. On the following day, the cells were transduced with Ad-LacZ, AdK7-LacZ, Ad-CAT, or AdK7-CAT at 300 or 3000 VP/cell for 2 h. After a 48-h incubation, the medium was exchanged for normal medium containing 30 mM menadione (Sigma Chemical), which is a ROS inducer. On the following day, the cell viability was determined by Alamar blue staining (BioSource, San Diego, CA).

2.5. Catalase activities in the liver after intravenous administration of Ad vectors

Ad vectors (Ad-LacZ, AdK7-LacZ, Ad-CAT, and AdK7-CAT) were intravenously administered into C57BL/6 mice (7–8-week-old females; Nippon SLC, Shizuoka, Japan) at a dose of 1×10^{10} VP/mice. Forty-eight hours later, the livers were isolated and homogenized with 50 mM potassium phosphate buffer containing 1 mM EDTA. The supernatants were recovered after centrifugation of the homogenates, and catalase activity in the supernatants was measured using a CalBiochem Catalase Assay Kit (Calbiochem).

2.6. Hepatic ischemia/reperfusion experiment

Mice were intravenously administered PBS (control) or Ad vectors via the tail vein at a dose of 10^{10} VP/mice. A partial hepatic ischemia/reperfusion experiment was performed as previously described [36,37]. Briefly, 2 days post-administration of Ad vectors, mice were anesthetized with a peritoneal injection of pentobarbital sodium (50 mg/kg). An incision was made in the abdomen, and all structures in the portal triad (hepatic artery, portal vein, bile duct) were occluded with a vascular clamp for 1 h to induce hepatic ischemia. Then, blood was allowed to flow through the liver again by removal of the clamp (reperfusion). After an appropriate period of reperfusion (0, 1, 6, 24 h), blood was collected via retro-orbital bleeding, and serum was obtained by centrifugation. The aspartate aminotransferase (ALT) and alanine aminotransferase (AST) activities in serum, as indicators of liver injury during reperfusion, were assayed using a transaminase-CII test (Wako, Osaka, Japan). In separate experiments, histology in the liver sections was evaluated 24 h after reperfusion. The livers were recovered and fixed by immersion in 10% buffered formalin, embedded in paraffin and processed for histology. Tissue damage was assessed in hematoxylin and eosin-stained sections. A sham surgery was performed under anesthesia but without occluding the vessels.

2.7. CCl_4 -induced liver injury experiment

Ad vectors were intravenously administered into mice as described above. Forty-eight hours after Ad vector injection, CCl_4 dissolved in olive oil was intraperitoneally administered to the mice at a dose of 1 ml/kg body weight to induce acute liver failure. Twenty-four hours after CCl_4 administration, blood was collected via retro-orbital bleeding, and the levels of ALT and AST in the serum were determined as described above.

2.8. Partial hepatectomy

Ad vectors were intravenously administered into mice as described above. Forty-eight hours after Ad vector injection, mice were anesthetized and subjected to two-thirds hepatectomy as described previously [38,39]. Subsequently, liver I/R was conducted by occlusion of the blood vessel to block the blood flow into the remnant liver for 8 min followed by reperfusion as described above. After the surgery, the mice were maintained under conventional conditions to monitor survival rates.

2.9. Statistical analysis

Results were expressed as the means \pm S.D. Statistically significant differences between groups were determined by the two-way analysis of variance, followed by Student's *t*-test. The levels of statistical significance were set at $p < 0.05$ and $p < 0.01$.

3. Results

3.1. Ad vector-mediated catalase expression *in vitro*

First, to examine *in vitro* catalase expression levels following Ad vector infection, Western blotting analysis was performed. We observed an apparent increase in the catalase expression after transduction with Ad-CAT or AdK7-CAT in A549 cells (Fig. 1). In addition, AdK7-CAT mediated higher catalase expression than Ad-CAT, probably due to the higher transduction activity of AdK7 vectors than conventional Ad vectors [35]. The control Ad vectors, Ad-LacZ and AdK7-LacZ, did not increase catalase expression, indicating that transduction with Ad vectors alone does not induce any change in the antioxidant systems.

Next, to examine whether Ad vector-mediated over-expression of catalase prevents ROS-induced cellular toxicity, the cells were incubated with 30 mM menadione following transduction with Ad vectors, and the cell viabilities were determined. It is well known that menadione produces superoxide radicals in cells, leading to oxidative stress-induced cell death [40,41]. As shown in Fig. 2, the cell viability was significantly reduced to less than 50% in the presence of 30 mM menadione. In contrast, transduction with catalase-expressing Ad vectors dramatically improved the cell viabilities. Transduction with Ad-CAT and AdK7-CAT at 300 VP/cell resulted in cell viabilities of 70.8% and 79.1% of the cell, respectively. These results indicate that Ad vector-mediated over-expression of catalase is beneficial in preventing oxidative stress-induced cell death by efficiently deleting ROS.

3.2. Catalase activity in the liver following catalase-expressing Ad vector injection

Next, to measure catalase activities in the liver following intravenous administration of Ad vectors, the livers were recovered 48 h after Ad vector injection, and catalase activities in the liver were determined. The catalase activities were 2.4-fold and 4.3-fold increased following administration of Ad-CAT and AdK7-CAT, respectively (Fig. 3). By contrast, we found no elevation in the catalase activity by LacZ-expressing Ad vectors. These results indicate that catalase activity in the liver is significantly elevated by intravenous administration of catalase-expressing Ad vectors.

3.3. Prevention of hepatic I/R injury by pre-administration of catalase-expressing Ad vectors

To evaluate the ability of catalase-expressing Ad vectors to prevent hepatic I/R injury, serum ALT and AST levels were measured after 1 h of hepatic ischemia followed by reperfusion. Both serum ALT and AST levels were highly elevated at 1 h and 6 h after the reperfusion of hepatic flows in the mice pre-injected with PBS, indicating that hepatic injury was induced by I/R (Fig. 4). At 1 h after reperfusion, the ALT and AST levels increased from 59.3 to 184.0 and from 421.2 to 1174.7 IU/L, respectively. However, pretreatment with Ad-CAT or AdK7-CAT significantly reduced the serum ALT and AST levels at 6 h after reperfusion. The ALT and AST levels in mice pre-injected with AdK7-CAT were 3.9- and 4.4-fold lower than those in mice pre-injected with PBS. Reductions in the ALT and AST levels were also observed at 1 h after reperfusion, although these changes were not statistically significant. The control Ad vectors, Ad-LacZ and AdK7-LacZ, exhibited no suppressive effects on the I/R-induced elevation of serum ALT and AST levels.

Furthermore, to histologically evaluate the preventive effects of catalase-expressing Ad vectors, liver sections were prepared 24 h after reperfusion. An extensive necrotic area was observed in the mice pretreated with PBS or AdK7-LacZ (Fig. 5B, C). In contrast, transduction with Ad-CAT or AdK7-CAT resulted in a dramatic decrease in the necrotic area induced by hepatic I/R (Fig. 5D, E). In particular,




Fig. 1. Catalase expression following Ad vector transduction. A549 cells were transduced with Ad-LacZ, Ad-CAT, or AdK7-CAT at 3000 VP/cell for 2 h. Protein samples were collected after a 48-h incubation and analyzed by Western blotting. Lane 1, mock; lane 2, Ad-LacZ; lane 3, AdK7-LacZ; lane 4, Ad-CAT; lane 5, AdK7-CAT. The results are representative of two




Fig. 2. Protective effects of catalase-expressing Ad vectors against menadione-induced cell death. HepG2 cells were transduced with Ad vectors at 300 or 3000 VP/cell for 2 h. After a 48-h incubation, menadione was added to the medium at a final concentration of 30 mM, and the cells were cultured for an additional 24 h. The cellular viabilities were then determined by Alamar blue staining. The cellular viabilities were normalized to the viability of Ad vector-infected HepG2 cells in the absence of menadione. The data are expressed as the means \pm S.D. ($n=4$). **Significantly different from the mock-infected group at $p<0.01$.

pre-injection of AdK7-CAT almost completely prevented necrosis in the liver, although there were several small necrotic areas in the liver pretreated with Ad-CAT, probably due to the higher transduction efficiency and less liver toxicity profile of AdK7 vectors in the liver compared with conventional Ad vectors [24]. A TUNEL assay indicated that Ad-CAT and AdK7-CAT prevented the DNA fragmentation caused by hepatic I/R in hepatocytes (data not shown). These results indicate that the I/R-induced histological damages were also significantly attenuated by pretreatment with catalase-expressing Ad vectors.

3.4. Preventive effect of catalase-expressing Ad vectors on CCl_4 -induced liver injury

To explore whether Ad vector-mediated catalase expression prevents other types of oxidative stress-induced liver injury, CCl_4 was intraperitoneally injected into mice pretreated with catalase-expressing Ad vectors. CCl_4 is well known to produce CCl_3 radical, leading to acute liver injury. Serum ALT and AST levels were highly elevated following CCl_4 treatment in mice pretreated with PBS or LacZ-expressing Ad vectors (Fig. 6). However, serum ALT and AST levels were markedly reduced by pretreatment with Ad-CAT and AdK7-CAT. AdK7-CAT mediated a 4.9-fold and 3.9-fold reduction in serum ALT and AST levels, respectively, compared with PBS. Ad-CAT and AdK7-CAT also mediated a dramatic improvement of CCl_4 -




Fig. 3. Catalase activity in the liver following intravenous administration of catalase-expressing Ad vectors. Ad vectors were administered to mice at the dose of 1×10^{10} VP/mouse. The livers were recovered 48 h after injection, and catalase activities in mouse liver homogenates were determined. The data are expressed as the means \pm S.D. ($n=5$). **Significantly different from the mock-infected group at $p<0.01$.




Fig. 4. Effects of pre-administration of catalase-expressing Ad vectors on serum ALT (A) and AST (B) levels in mice following hepatic ischemia/reperfusion injury. Ad vectors were intravenously administered to mice at a dose of 1×10^{10} VP/mice. Forty-eight hours after Ad vector injection, mice were subjected to a 1 h period of ischemia followed by hepatic reperfusion. Serum samples were taken at 1 h before ischemia, and 0, 1, 6, and 24 h after reperfusion. The data are expressed as the mean \pm S.E. ($n=3-8$). **Significantly different from the PBS-injected group at $p<0.01$.

induced gross abnormality in the liver (data not shown). These results indicate that catalase-expressing Ad vectors possess preventive effects on oxidative stress-induced injury that are distinct from their effects on I/R injury.




Fig. 5. Representative images of liver sections of mice 24 h following hepatic ischemia/reperfusion. A) Sham, B) PBS, C) AdK7-LacZ, D) Ad-CAT, and E) AdK7-CAT. Mice were subjected to hepatic I/R 48 h after Ad vector injection, as described in Fig. 4. Livers were recovered 24 h after I/R treatment, and liver sections stained with hematoxylin and eosin were observed under a microscope. A dashed line indicates the necrotic area. The scale bar represents 100 μm .




Fig. 6. Preventive effect of catalase-expressing Ad vectors on CCl_4 -induced acute liver failure. CCl_4 (1 ml/kg) was intraperitoneally injected to mice 48 h following Ad vector injection. Serum samples were collected 24 h after CCl_4 administration. The data are expressed as the means \pm S.D. ($n = 4$). *Significantly different from the PBS-injected group at $p < 0.05$; ** at $p < 0.01$.

3.5. Improvement of survival rates of mice subjected to partial hepatectomy and hepatic ischemia/reperfusion by catalase-expressing Ad vectors

To examine whether over-expression of catalase improves the remnant liver function in mice subjected to both partial hepatectomy and I/R treatment, partial hepatectomy and subsequent I/R treatment were conducted 48 h after pre-administration of Ad vectors. Partial hepatectomy is often performed under hepatic ischemia, and the remaining liver suffers from I/R injury after partial hepatectomy in clinical settings. Mice pre-administered with AdK7-CAT showed a dramatic improvement in survival rate (Fig. 7). Seventy percent of mice survived for 7 days after these treatments. The body weights of the mice pre-injected with AdK7-CAT were not significantly reduced 7 days after surgery, compared with those before surgery (data not shown), suggesting that the general health of the mice was not substantially compromised after the surgery. On the other hand, the survival of the mice was not prolonged by pre-administration of Ad-LacZ or PBS. These results indicate that catalase-expressing Ad vectors are able to protect the liver from more serious stress induced by partial hepatectomy and I/R, and to improve the remnant liver function.

4. Discussion

Hepatotoxins, drugs, and I/R can injure the liver via oxidative stress. With the aim of efficiently preventing oxidative stress-induced hepatic




Fig. 7. Survival rates of mice subjected to partial hepatectomy and hepatic I/R following Ad vector administration. Solid line: PBS ($n = 5$); dotted line: AdK7-LacZ ($n = 7$); dashed line: AdK7-CAT ($n = 11$). Ad vectors were intravenously administered to mice as described in Fig. 4. Forty-eight hours after Ad vector administration, mice were subjected to two-thirds partial hepatectomy, followed by an 8 min-period of ischemia

injury, we pre-administered Ad vectors expressing an antioxidative enzyme, catalase, to mice. The results of our study demonstrated that Ad vector-mediated over-expression of catalase in the liver effectively prevents hepatic injury caused by not only I/R but also CCl_4 . Furthermore, the survival rates of mice subjected to both partial hepatectomy and I/R treatment were prolonged by over-expression of catalase.

Superoxide anion is the primary oxidant species generated during hepatic I/R by a xanthine oxidase system and/or decoupling of the electron transport system in mitochondria. Superoxide anion is readily converted to H_2O_2 by SOD or a spontaneous reaction. H_2O_2 itself is a weak oxidizing agent; however, hydroxyl radical is produced by H_2O_2 in the presence of transition-metal ion. Hydroxyl radical has the most oxidative ability and the strongest toxicity among the various ROS. Reduction/elimination of hydroxyl radical is considered to be the most effective strategy for prevention of hepatic I/R injury. Therefore, catalase, which prevents generation of hydroxyl radical by converting H_2O_2 to H_2O and O_2 , was selected as the antioxidant enzyme in the present study. Catalase derivatives also exhibited higher preventive effects on the elevation of serum ALT and AST levels induced by hepatic I/R, compared with SOD derivatives [5,6]. In addition, over-expression of catalase in the liver might increase endogenous expression of SOD, which is another advantage of catalase gene transfer. He et al. demonstrated that delivery of catalase gene alone to the liver induced SOD activity in the liver [17].

Partial hepatectomy is often performed under hepatic ischemia. Previous studies have shown that oxidative stress induced by hepatic I/R affects hepatocyte cell death and inhibits liver regeneration [42,43]. Beyer et al. reported that ROS are directly responsible for the impairment of insulin/insulin-like growth factor 1 signaling, which is crucial for liver regeneration [44]. Furthermore, hepatocytes without catalase activity have been found in regenerating livers after partial hepatectomy [45], suggesting that hepatocytes in the regenerating livers might be susceptible for ROS-mediated injury. The present study demonstrated that over-expression of catalase in the liver dramatically improved the survival rates of mice subjected to partial hepatectomy and I/R, suggesting that the remnant livers would be protected from ROS-mediated injury by over-expression of catalase. Furthermore, over-expression of catalase might play an important role in maintenance of the regenerative capacity of hepatocytes. Recently, removal of ROS by antioxidant enzymes was demonstrated to be crucial for maintenance of the self-renewal capacity of progenitor/stem cells in an *in vitro* culture system [46,47]. In this study, the liver/body weight ratio of mice pre-injected with AdK7-CAT 1 week after partial hepatectomy and I/R was $4.7 \pm 0.55\%$, which is not significantly different from that of naïve mice (data not shown).

Oxidative stress is also generated in the liver through metabolism of a variety of drugs, chemicals, and toxins, such as thioacetamide, lipopolysaccharide, and CCl_4 . In particular, CCl_4 is often used as a representative hepatotoxin causing oxidative stress in animal experiments. CCl_4 is metabolized by cytochrome P450 in the endoplasmic reticulum of hepatocytes, leading to generation of CCl_3 radical, which induces hepatic damages, although the mechanism of CCl_4 -mediated liver damage has not yet been fully revealed. The present study showed that Ad vector-mediated over-expression of catalase in the liver also attenuated CCl_4 -induced liver injury (Fig. 6). Over-expression of SOD has also been shown to inhibit CCl_4 -induced hepatic damages [48]. Hepatic delivery of genes encoding ROS-deleting enzymes is effective in case of hepatic injury induced by oxidative stress-generating hepatotoxins and chemical compounds.

Ad vectors offer various advantages for gene delivery to the liver; however, systemic administration of Ad vectors often induces inflammatory cytokine production and hepatic damage [24,49–51]. However, we found no apparent Ad vector-induced damages in the liver in this study (data not shown). Moreover, mice pre-administered Ad-LacZ or AdK7-LacZ did not exhibit higher levels of serum ALT and AST after I/R than those pre-administered PBS (Fig. 4). This was likely

due to the relatively low dose of Ad vectors (1×10^{10} VP/mouse) used in this study. Higher doses of Ad vectors have often been administered in the studies reporting Ad vector-mediated *in vivo* toxicities [49,51]. We confirmed that more than 90% of hepatocytes were efficiently transduced even at a dose of 1×10^{10} VP/mouse in this study (data not shown). In general, Ad vectors have been considered more toxic than non-viral vectors containing plasmid DNA; however, our group recently revealed that Ad vectors induced smaller amounts of inflammatory cytokines, which are partly involved in Ad vector-induced hepatic toxicity, following intravenous administration into mice, compared with plasmid DNA/cationic liposome complexes, which were used as a representative of non-viral gene delivery vehicle [23]. In both that previous study and our present work, Ad vectors successfully deliver antioxidant genes to the liver with no apparent toxicity, although we should pay attention to the vector doses.

In addition to conventional Ad vectors, fiber-modified AdK7 vectors, which display a poly-lysine motif on the c-terminal of the fiber knob, [24,35,52] were used in this study. AdK7 vectors mediate not only significantly higher transgene expression in the liver but also lower *in vivo* damages than conventional Ad vectors [24]. However, the serum ALT and AST levels of the mice receiving Ad-CAT and AdK7-CAT were not significantly different from those of the controls in this study (Fig. 4), although histological analysis of the liver sections revealed that AdK7-CAT conferred superior protection against I/R injury (Fig. 5), probably because sufficient levels of catalase would be expressed by Ad-CAT at this dose to prevent hepatic I/R-induced increases in serum ALT and AST in this setting. AdK7-CAT might show higher protective effects than conventional Ad vectors under more severe conditions.

In conclusion, the present study demonstrated that Ad vector-mediated catalase expression in the liver significantly improved I/R-induced hepatic injury. These findings suggest that Ad vectors expressing antioxidant enzymes would contribute to the development of strategies aimed at inhibiting hepatic I/R injury. Antioxidant enzyme-expressing Ad vectors are also applicable for the prevention of I/R-induced injury in other organs and oxidative stress-induced damages caused by ROS-generating chemicals. Moreover, their combined use with other antioxidant genes or anti-apoptosis genes could further attenuate oxidative stress-induced injury.

Acknowledgement

We thank Dr. Yuriko Higuchi (Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan) for her help in the liver ischemia/reperfusion experiments. We also thank Dr. Kazuo Ohashi (Institute of Advanced Biomedical Engineering and Sciences, Tokyo Women's Medical University, Tokyo, Japan) for his help in the partial hepatectomy experiment. This work was supported by grants from the Ministry of Health, Labour, and Welfare of Japan.

References

- [1] R.G. Thurman, et al., Hepatic reperfusion injury following orthotopic liver transplantation in the rat, *Transplantation* 46 (1988) 502–506.
- [2] J.M. McCord, Oxygen-derived free radicals in postischemic tissue injury, *N. Engl. J. Med.* 312 (1985) 159–163.
- [3] M.J. Arthur, et al., Oxygen-derived free radicals promote hepatic injury in the rat, *Gastroenterology* 89 (1985) 1114–1122.
- [4] D.N. Granger, R.J. Korhuis, Physiologic mechanisms of postischemic tissue injury, *Annu. Rev. Physiol.* 57 (1995) 311–332.
- [5] Y. Yabe, et al., Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives, *J. Pharmacol. Exp. Ther.* 298 (2001) 894–899.
- [6] Y. Yabe, et al., Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives, *J. Pharmacol. Exp. Ther.* 289 (1999) 1176–1184.
- [7] S.L. Atalla, L.H. Toledo-Pereyra, G.H. MacKenzie, J.P. Cederna, Influence of oxygen-derived free radical scavengers on ischemic livers, *Transplantation* 40 (1985) 584–590.
- [8] T. Fujita, et al., Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion, *Biochem. Biophys. Res. Commun.* 189 (1992) 191–196.
- [9] P.S. Pyatak, A. Abuchowski, F.F. Davis, Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity, *Res. Commun. Chem. Pathol. Pharmacol.* 29 (1980) 113–127.
- [10] J.F. Turrens, J.D. Crapo, B.A. Freeman, Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase, *J. Clin. Invest.* 73 (1984) 87–95.
- [11] L. Agrawal, et al., Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis, *Gene Ther.* 13 (2006) 1645–1656.
- [12] P.Y. Benhamou, et al., Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets, *Diabetologia* 41 (1998) 1093–1100.
- [13] E. Durand, et al., Adenovirus-mediated gene transfer of superoxide dismutase and catalase decreases restenosis after balloon angioplasty, *J. Vasc. Res.* 42 (2005) 255–265.
- [14] F. Sakurai, H. Mizuguchi, T. Yamaguchi, T. Hayakawa, Characterization of *in vitro* and *in vivo* gene transfer properties of adenovirus serotype 35 vector, *Mol. Ther.* 8 (2003) 813–821.
- [15] H. Mizuguchi, et al., CAR- or alpha integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice, *Gene Ther.* 9 (2002) 769–776.
- [16] R. Alemany, D.T. Curiel, CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors, *Gene Ther.* 8 (2001) 1347–1353.
- [17] S.Q. He, et al., Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice, *Liver Transpl.* 12 (2006) 1869–1879.
- [18] H. Yin, et al., Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury, *Biochem. Biophys. Res. Commun.* 351 (2006) 940–946.
- [19] R.S. Sung, L. Qin, J.S. Bromberg, TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression, *Mol. Ther.* 3 (2001) 757–767.
- [20] N. Morral, et al., Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors, *Hum. Gene Ther.* 8 (1997) 1275–1286.
- [21] S. Li, L. Huang, *In vivo* gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes, *Gene Ther.* 4 (1997) 891–900.
- [22] S. Li, et al., Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors, *Am. J. Physiol.* 276 (1999) L796–L804.
- [23] H. Sakurai, et al., Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipoplex, *J. Control. Release* 117 (2007) 430–437.
- [24] N. Koizumi, et al., Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production, *J. Immunol.* 178 (2007) 1767–1773.
- [25] M.D. Wheeler, et al., Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury, *Hum. Gene Ther.* 12 (2001) 2167–2177.
- [26] S. Kondo, et al., Mannosylated superoxide dismutase inhibits hepatic reperfusion injury in rats, *J. Surg. Res.* 60 (1996) 36–40.
- [27] B. Chen, et al., Delivery of antioxidant enzyme genes protects against ischemia/reperfusion-induced injury to retinal microvasculature, *Invest. Ophthalmol. Vis. Sci.* 50 (2009) 5587–5595.
- [28] H. Mizuguchi, M.A. Kay, Efficient construction of a recombinant adenovirus vector by an improved *in vitro* ligation method, *Hum. Gene Ther.* 9 (1998) 2577–2583.
- [29] H. Mizuguchi, M.A. Kay, A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors, *Hum. Gene Ther.* 10 (1999) 2013–2017.
- [30] H. Mizuguchi, et al., A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob, *Gene Ther.* 8 (2001) 730–735.
- [31] M. Mari, J. Bai, A.I. Cederbaum, Adenovirus-mediated overexpression of catalase in the cytosolic or mitochondrial compartment protects against toxicity caused by glutathione depletion in HepG2 cells expressing CYP2E1, *J. Pharmacol. Exp. Ther.* 301 (2002) 111–118.
- [32] J. Bai, A.I. Cederbaum, Adenovirus-mediated overexpression of catalase in the cytosolic or mitochondrial compartment protects against cytochrome P450 2E1-dependent toxicity in HepG2 cells, *J. Biol. Chem.* 276 (2001) 4315–4321.
- [33] F. Sakurai, et al., Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities, *Gene Ther.* 12 (2005) 1424–1433.
- [34] J.V. Maizel Jr., D.O. White, M.D. Scharff, The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12, *Virology* 36 (1968) 115–125.
- [35] N. Koizumi, et al., Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob, *J. Gene Med.* 5 (2003) 267–276.
- [36] A. Tsung, et al., The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion, *J. Exp. Med.* 201 (2005) 1135–1143.
- [37] M.R. Duranski, et al., Cytoprotective effects of nitrite during *in vivo* ischemia-reperfusion of the heart and liver, *J. Clin. Invest.* 115 (2005) 1232–1240.
- [38] K. Ohashi, F. Park, M.A. Kay, Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction *in vivo*, *Hum. Gene Ther.* 13 (2002) 653–663.
- [39] K. Ohashi, et al., Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases, *Hepatology* 41 (2005) 132–140.
- [40] T.J. Monks, et al., Quinone chemistry and toxicity, *Toxicol. Appl. Pharmacol.* 112 (1992) 2–16.
- [41] H. Thor, et al., The metabolism of menadione (2-methyl-, 4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells, *J. Biol. Chem.* 257 (1982) 12419–12425.
- [42] N. Fausto, Liver regeneration, *J. Hepatol.* 32 (2000) 19–31.

- [43] H. Kamata, et al., Reactive oxygen species promote TNF α -induced death and sustained JNK activation by inhibiting MAP kinase phosphatases, *Cell* 120 (2005) 649–661.
- [44] T.A. Beyer, et al., Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance, *Embo J.* 27 (2008) 212–223.
- [45] I. Oikawa, P.M. Novikoff, Catalase-negative peroxisomes: transient appearance in rat hepatocytes during liver regeneration after partial hepatectomy, *Am. J. Pathol.* 146 (1995) 673–687.
- [46] R.C. Meagher, A.J. Salvado, D.G. Wright, An analysis of the multilineage production of human hematopoietic progenitors in long-term bone marrow culture: evidence that reactive oxygen intermediates derived from mature phagocytic cells have a role in limiting progenitor cell self-renewal, *Blood* 72 (1988) 273–281.
- [47] R. Gupta, S. Karparkin, R.S. Basch, Hematopoiesis and stem cell renewal in long-term bone marrow cultures containing catalase, *Blood* 107 (2006) 1837–1846.
- [48] S.K. Venugopal, et al., Lentivirus-mediated superoxide dismutase1 gene delivery protects against oxidative stress-induced liver injury in mice, *Liver Int.* 27 (2007) 1311–1322.
- [49] M. Christ, et al., Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products, *Hum. Gene Ther.* 11 (2000) 415–427.
- [50] A. Lieber, et al., Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver, *J. Virol.* 72 (1998) 9267–9277.
- [51] R.S. Everett, et al., Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors, *Hum. Gene Ther.* 14 (2003) 1715–1726.
- [52] T.J. Wickham, et al., increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins, *J. virol.* 71 (1997) 8221–8229.

Potency of Claudin-targeting as Antitumor Therapy

Rie Saeki¹, Masuo Kondoh¹, Hiroshi Uchida² and Kiyohito Yagi¹

¹Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; ²Department of Biopharmaceuticals Research, Biopharma Center, Asubio Pharma Co., Ltd., Gunma 370-0503, Japan

PharmSight on Saeki R et al., A novel tumor-targeted therapy using a claudin-4-targeting molecule. *Mol Pharmacol* 2009;76:918-26.

Abstract

Approximately 90% of malignant tumors are derived from the epithelium. Epithelium has well-developed tight junctions (TJs), which become deregulated and disrupted during epithelial transformation. Claudin-4, a pivotal functional and structural component of TJs, is often overexpressed in human cancers. In the present study, we prepared a claudin-4 binder, the C-terminal fragment of *Clostridium perfringens* enterotoxin (C-CPE), fused to a cytotoxic molecule (C-CPE-PSIF) and found that C-CPE-PSIF is toxic to claudin-4-expressing cells. Interestingly, C-CPE-PSIF was less toxic in polarized than depolarized cells, and treatment of polarized cells with C-CPE-PSIF from the basal but not apical side was cytotoxic. C-CPE-PSIF also exhibits antitumor activity. C-CPE mutants with alanine substitutions were more cytotoxic than C-CPE. These findings indicate that the claudin-4 binder, C-CPE, is a potent lead molecule for the development of claudin-targeted tumor therapy.

Keywords: Claudin; *Clostridium perfringens* enterotoxin; *Pseudomonas* exotoxin; Anti-tumor activity

Introduction

Tight junctions (TJs) consist of three main classes of proteins: claudins, occludin, and junctional adhesion molecules. Claudins regulate the integrity

and function of TJs (1). The human family of claudin proteins contains at least 23 members, and their expression profiles and functions are tissue and cell specific (2). Changes in claudin expression occur in malignant tumors, and the expression profiles differ among tissues (3, 4). For example, claudin-1 and -10 are overexpressed in colon and hepatocellular cancer cells, respectively (3), while claudin-4 is up-regulated in breast, ovarian, pancreatic, colorectal, hepatic and bladder cancers (Table 1). Thus, claudins are potential targets for tumor therapy. However, claudin has low antigenicity, and it is difficult to generate antibodies to the extracellular region of claudins.

Clostridium perfringens enterotoxin (CPE) is a single polypeptide of 35 kDa that causes food poisoning in humans. The functional domains of CPE are classified into the N-terminal cytotoxic and C-terminal receptor-binding regions (5, 6). Two years after the CPE receptor was identified in 1997, it was found to be identical to claudin-4 (7, 8). Interestingly, C-terminal CPE, which corresponds to amino acids 184 to 319 (C-CPE₁₈₄₋₃₁₉), binds to claudin-4 and inhibits TJ function. We previously found that C-CPE₁₈₄₋₃₁₉ is a useful ligand for claudin-4 (9). However, C-CPE₁₈₄₋₃₁₉ has poor solubility (0.3 mg/ml) and is difficult to use in pharmaceutical therapy. In 2008, Van Itallie et al. showed that a slightly smaller polypeptide, C-CPE₁₉₄₋₃₁₉, has high solubility (>10 mg/ml) and high affinity to claudin-4 (10).

Pseudomonas aeruginosa exotoxin A (PE) is widely used in cancer-targeting study (11). PE binds to the cell surface and is internalized via endocytosis; then, a PE fragment, protein synthesis inhibitory factor (PSIF), escapes from the endosome to the cytosol (12), where it inhibits protein synthesis by inhibiting elongation factor 2. PSIF lacks the receptor-binding domain of PE, and fusion of a tumor

Received 11/25/09; accepted 02/24/10

Correspondence: Dr. Masuo Kondoh, Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan. Tel. 81-6-6879-8196, Fax. 81-6-6879-8199. e-mail: masuo@phs.osaka-u.ac.jp; Dr. Kiyohito Yagi, Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan. Tel. 81-6-6879-8195, Fax. 81-6-6879-8195. e-mail: yagi@phs.osaka-u.ac.jp

Table 1 Changes in expression of claudin-4 in cancer cells

Cancer	Expression	References
Prostate	Up	(25)
Breast	Up	(26, 27)
Ovarian	Up	(28-31)
Pancreatic	Up	(32-34)
Colorectal	Up	(35)
Uterus	UP	(36, 37)
Gastric	Down	(38, 39)
Hepatocellular	Up	(40)

antigen ligand with PSIF is a promising strategy for cancer-targeting therapy.

In the present study, we genetically prepared a claudin-4-targeting molecule (C-CPE₁₉₄₋₃₁₉-PSIF) containing the claudin-4-binding region of CPE and PSIF (Figure 1A). We also investigated whether C-CPE₁₉₄₋₃₁₉ (referred to as C-CPE hereafter) is useful for claudin-4-targeted cancer therapy.

Results and Discussion

L cells, which are a mouse fibroblast cell line, do not express any claudins. Therefore, we investigated the cytotoxicity of C-CPE-PSIF in claudin-4-expressing L cells (CL4/L cells). C-CPE-PSIF caused dose-dependent cytotoxicity in CL4/L cells, reaching >90% cell death at 10 ng/ml. In contrast, even at 20 ng/ml, PSIF was not cytotoxic to CL4/L cells (13). C-CPE-PSIF showed specific toxicity in CL4/L cells, and pretreatment of the cells with C-CPE attenuated the C-CPE-PSIF-induced cytotoxicity, indicating that C-CPE-PSIF may interact with claudin-4 via its C-CPE domain (13).

Claudin-4 is expressed in tissues including the lung, intestine, liver, and kidney. Most claudins in normal cells are contained in TJ complexes, whereas the localization of claudin is deregulated in some cancers. C-CPE-PSIF may recognize the deregulated localization of claudin-4. Confluent Caco-2 cells form a polarized cell monolayer with well-developed TJs, and they are frequently used as a model of polarized cells. Confluent Caco-2 cells express more claudin-4 than pre-confluent cells; however, C-CPE-PSIF was more toxic in the pre-confluent cells with fewer TJs

(47% cell death at 5 ng/ml) than in the confluent cells with well-developed TJs (40% cell death, even at 200 ng/ml) (13).

Early events in epithelial carcinogenesis are deregulation of cellular polarity and loss of TJ structures. We examined whether the sensitivity of cells to C-CPE-PSIF is affected by their cellular polarity using Caco-2 monolayer cell sheets grown on the membrane in Transwell chambers. The Caco-2 monolayer cells exhibit a well-differentiated brush border containing TJs on the apical surface, and they are frequently used as an epithelial cell sheet model. After the addition of C-CPE-PSIF to the apical or basolateral compartment of the Transwell chamber, we assessed the TJ barrier function of the cell sheets by measuring transepithelial electric resistance (TER). When C-CPE-PSIF was added to the apical compartment, TER was not affected for 48 h. In contrast, the addition of C-CPE-PSIF to the basolateral compartment caused a significant and dose-dependent reduction in TER. Furthermore, the addition of C-CPE-PSIF to the basolateral compartment, but not the apical compartment, increased the amount of released lactate dehydrogenase, a marker of cytotoxicity (13). These results indicate that C-CPE-PSIF has specific effects based on the cellular density and polarity.

We examined the antitumor activity of C-CPE-PSIF in 4T1 cells, a mouse breast cancer cell line that expresses claudin-4. To clarify the antitumor activity of the claudin-4-targeting molecule (C-CPE-PSIF), we prepared a fusion protein of PSIF with mutant C-CPE, in which Tyr306 and Leu315 (critical residues for the interaction between C-CPE

and claudin-4) were changed to alanines, resulting in C-CPE_{Y306A/L315A}-PSIF (14). C-CPE-PSIF mediated dose-dependent cytotoxicity in 4T1 cells, reaching 63% cell death at 100 ng/ml. In contrast, C-CPE_{Y306A/L315A}-PSIF was not cytotoxic even at 500 ng/ml, indicating that the cytotoxicity of C-CPE-PSIF in 4T1 cells may be mediated by its binding to claudin-4. To investigate the in vivo antitumor activity of C-CPE-PSIF, 4T1 cells (2×10^6 cells) were inoculated into the right flank of mice on day 0. Vehicle, C-CPE, C-CPE-PSIF or C-CPE_{Y306A/L315A}-PSIF at a dose of 5 μ g/kg was intratumorally injected on days 2, 4, 7, 9, 11, and 14. C-CPE-PSIF significantly suppressed tumor growth, and the tumor volume in the C-CPE-PSIF-treated group was 36% of that in the vehicle-treated group on day 16. In contrast, C-CPE and C-CPE_{Y306A/L315A}-PSIF, which lacked claudin-4-binding activity, had no effect on tumor growth, indicating that the antitumor activity of C-CPE-PSIF may depend on claudin-4 targeting (13).

We previously investigated the functional domains of C-CPE and found that the 16 C-terminal amino acids of C-CPE are involved in claudin-4 binding; we also found that the claudin-4 affinities of the N309A mutant, which contains Ala instead of Asn at position 309, and the S313A mutant, which contains Ala instead of Ser at position 313, were greater than that of C-CPE (14, 15). To improve the claudin-4-targeting molecule, we prepared C-CPE_{S313A}-PSIF and C-CPE_{N309A/S313A}-PSIF (Figure 1A). C-CPE_{S313A}-PSIF and C-CPE_{N309A/S313A}-PSIF were more cytotoxic than C-CPE-PSIF in CL4/L cells (Figure 1B). We are currently investigating the antitumor activity of these mutants and developing other C-CPE mutant-PSIF constructs with greater cytotoxicity. To develop novel methods of tumor diagnosis and therapies that target the initial stage of malignant transformation, we are also developing novel claudins binders, in addition to optimizing C-CPE, the conventional claudin-binder.

Perspective of claudin-targeted tumor therapy

Approximately 7.6 million people worldwide die from cancer each year, and 90% of malignant tumors are derived from epithelial tissues (16) (<http://www.reuters.com/article/healthNews/idUSN1633064920071217>).

Cancer cells grow slowly during the very early stage of malignant transformation, after which they grow exponentially and form tumor tissues. Tumors that reach a mass of 10^{12} cancer cells lead to death.




Figure 1. Cytotoxicity of C-CPE-PSIF fusion proteins (A) Schematic illustration of C-CPE-PSIF fusion proteins. C-CPE is the C-terminal fragment of CPE corresponding to amino acids 194-319. The dark area indicates the putative claudin-4-binding region (15). Changing Asn to Ala at position of 309 or Ser to Ala at position of 313 improved the affinity of C-CPE to claudin-4 (14). C-CPE_{S313A} or C-CPE_{N309A/S313A}-fused PSIF was also prepared. PSIF contains domain II (the critical domain for the escape of the toxin from the endosome to the cytosol) and domain III (the critical domain for the inhibition of protein synthesis) of *Pseudomonas* exotoxin. (B) Cytotoxicity of C-CPE-PSIF. CL4/L cells were treated with the C-CPE-PSIF fusion proteins at the indicated concentration for 24 h. The cellular viability was measured by a WST-8 assay kit, according to the manufacturer's instructions (Nacalai Tesque, Kyoto, Japan). Viability (%) was calculated as a percentage of the vehicle-treated cells. The data represent the mean \pm SD of three independent experiments.

Diagnosable cancer tumors contain at least 10^9 cells, and tumors with 10^9 - 10^{12} cells are subject to cancer therapy. An important goal in cancer therapy is improving the ability to detect tumors containing less than 10^9 cells so that they can be more successfully treated.

Epithelial tissues are characterized by specific cellular polarity. The establishment and maintenance of cell polarity involve many processes, including signaling cascades, membrane trafficking events and cytoskeletal dynamics, and relies on the apical junctional system, TJs (17, 18). TJs seal the intercellular space between adjacent cells and regulate the solute movement across epithelial

sheets. TJs between neighboring cells allow the separation of apical and basolateral membrane domains that vary in protein and lipid contents, resulting in the maintenance of cell polarity and the regulation of cellular proliferation (19). An important hallmark of malignant transformation is loss of epithelial polarity (20).


In normal polarized epithelial cells, the mitotic spindles are parallel to the epithelial planar axis, and cellular proliferation is regulated by intercellular contact. Cell-cell adhesion provides a cortical planar cue to orient the mitotic spindle parallel to the epithelial plane (21-23). In an early stage of epithelial tumorigenesis, the orientation of mitotic spindles becomes deregulated, resulting in out-of-plane division (24) (Figure 2). Cell division is controlled by cytoskeletal dynamics (i.e., the mitotic spindle, actin filaments and microtubules), and cell-cell adhesions and their associated molecules are thought to be connected to the cytoskeletal organization and partly control these cytoskeletal elements (22). Thus, misorientation of the cell division axis might cause changes in the function and localization of the cell-cell adhesion system.

Despite the lateral localization of TJs and their components in normal epithelial cell sheets, TJs and their components might be exposed on the cellular surface by the rotation of spindles, indicating that TJ components might be a therapeutic target during the early stage of epithelial tumorigenesis. Our goal is to develop a novel tumor-targeting therapy using the TJ components that are exposed to the apical membrane from the lateral membrane by rotation of the mitotic axis.

Acknowledgements

We thank Drs S. Tsunoda (National Institute of Biomedical Innovation, Osaka, Japan) and Y. Horiguchi (Osaka University, Osaka, Japan) for providing us PSIF cDNA and C-CPE cDNA, respectively. We also thank the members of our laboratory for their useful comments and discussion. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (21689006), by a Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan, by Takeda Science Foundation, by a Suzuken Memorial Foundation and by a grant from Kansai Biomedical Cluster project in Saito, which is promoted by the Knowledge Cluster Initiative of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Normal epithelia



Early stage of malignant transformation




Figure 2. Scheme of malignant transformation in epithelium. In normal epithelial cells, the cells are divided in parallel with the epithelial plane. In the early stage of epithelial tumorigenesis, the orientation of the mitotic spindles is deregulated, and the cells proliferate by out-of-plane division (24).

Conflicts of Interest

No potential conflicts of interest to disclose.

References

1. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players? *Trends Cell Biol* 1999;9:268-73.
2. Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. *Trends Cell Biol* 2006;16:181-8.
3. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. *Cancer Res* 2005;65:9603-6.
4. Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. *Adv Drug Deliv Rev* 2005;57:919-28.
5. Hanna PC, Wieckowski EU, Mietzner TA, McClane B A. Mapping of functional regions of *Clostridium perfringens* type A enterotoxin. *Infect Immun* 1992;60:2110-4.
6. McClane BA, Chakrabarti G. New insights into the cytotoxic mechanisms of *Clostridium perfringens* enterotoxin. *Anaerobe* 2004;10:107-14.
7. Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Molecular cloning and functional characterization of the receptor for *Clostridium perfringens* enterotoxin. *J Cell Biol* 1997;136:1239-47.
8. Sonoda N, Furuse M, Sasaki H, et al. *Clostridium perfringens* enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. *J Cell Biol* 1999;147:195-204.
9. Ebihara C, Kondoh M, Hasuike N, et al. Preparation of a claudin-targeting molecule using a C-terminal fragment of *Clostridium perfringens* enterotoxin. *J Pharmacol Exp Ther* 2006;316:255-60.

10. Van Itallie CM, Betts L, Smedley JG3rd, McClane BA, Anderson JM. Structure of the claudin-binding domain of *Clostridium perfringens* enterotoxin. *J Biol Chem* 2008;283:268-74.
11. Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. *Curr Drug Targets* 2006;7:1301-11.
12. Kreitman RJ. Immunotoxins in cancer therapy. *Curr Opin Immunol* 1999;11:570-8.
13. Saeki R, Kondoh M, Kakutani H, et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. *Mol Pharmacol* 2009;76:918-26.
14. Takahashi A, Komiya E, Kakutani H, et al. Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of *Clostridium perfringens* enterotoxin, by site-directed mutagenesis. *Biochem Pharmacol* 2008;75:1639-48.
15. Takahashi A, Kondoh M, Masuyama A, et al. Role of C-terminal regions of the C-terminal fragment of *Clostridium perfringens* enterotoxin in its interaction with claudin-4. *J Control Release* 2005;108:56-62.
16. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008;58:71-96.
17. Matter K, Aijaz S, Tsapara A, Balda MS. Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. *Curr Opin Cell Biol* 2005;17:453-8.
18. Matter K, Balda MS. Functional analysis of tight junctions. *Methods* 2003;30:228-34.
19. Vermeer PD, Einwalter LA, Moninger TO, et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. *Nature* 2003;422:322-6.
20. Wodarz A, Nathke I. Cell polarity in development and cancer. *Nat Cell Biol* 2007;9:1016-24.
21. Lu B, Roegiers F, Jan LY, Jan YN. Adherens junctions inhibit asymmetric division in the *Drosophila* epithelium. *Nature* 2001;409:522-5.
22. Reinsch S, Karsenti E. Orientation of spindle axis and distribution of plasma membrane proteins during cell division in polarized MDCKII cells. *J Cell Biol* 1994;126:1509-26.
23. Toyoshima F, Matsumura S, Morimoto H, Mitsushima M, Nishida E. PtdIns(3,4,5)P3 regulates spindle orientation in adherent cells. *Dev Cell* 2007;13:796-811.
24. Beamish H, de Boer L, Giles N, et al. Cyclin A/cdk2 regulates adenomatous polyposis coli-dependent mitotic spindle anchoring. *J Biol Chem* 2009;284:29015-23.
25. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of *Clostridium perfringens* enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. *Cancer Res* 2001;61:7878-81.
26. Kominsky SL, Vali M, Korz D, et al. *Clostridium perfringens* enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. *Am J Pathol* 2004;164:1627-33.
27. Tokes AM, Kulka J, Paku S, et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. *Breast Cancer Res* 2005;7:R296-305.
28. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. *Am J Pathol* 2004;165:397-414.
29. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. *Cancer Res* 2000;60:6281-7.
30. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. *Clin Cancer Res* 2003;9:2567-75.
31. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. *Int J Cancer* 2004;112:14-25.
32. Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. *Oncogene* 1996;13:1819-30.
33. Michl P, Buchholz M, Rolke M, et al. Claudin-4: a new target for pancreatic cancer treatment using *Clostridium perfringens* enterotoxin. *Gastroenterology* 2001;121:678-84.
34. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. *Am J Clin Pathol* 2004;121:226-30.
35. Mees ST, Mennigen R, Spieker T, et al. Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin. *Int J Colorectal Dis* 2009;24:361-8.
36. Santin AD, Bellone S, Siegel ER, et al. Overexpression of *Clostridium perfringens* enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. *Clin Cancer Res* 2007;13:3339-46.
37. Santin AD, Zhan F, Cane S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. *Br J Cancer* 2005;92:1561-73.
38. Lee SK, Moon J, Park SW, et al. Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. *Oncol Rep* 2005;13:193-9.
39. Soini Y, Tommola S, Helin H, Martikainen P. Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. *Virchows Arch* 2006;448:52-8.
40. Nishino R, Honda M, Yamashita T, et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. *J Hepatol* 2008;49:207-16.

《若手研究者紹介》



生体バリアの分子基盤を利用した創薬研究

近 藤 昌 夫* Masuo Kondoh

大阪大学大学院薬学研究科

1. は じ め に

オーストラリアの動物学者ローレンツは、動物の生活史のある特定の時期に特定の物事がごく短時間で覚えこまれその記憶が長期間に渡り持続する学習現象「刷り込み」を見出している。小職の研究における刷り込みは、学部3回生の時に恩師の生物薬剤学の講義の中で聞いた「細胞製剤：細胞を敬え、細胞に学べ」という言葉である。本稿では、恩師による刷り込みを経て生体バリアの分子基盤を利用した創薬研究に至るまでの経緯を振り返ってみたい。

入学後テニスに明け暮れていた小職は3回生に進学してから、少しずつ研究室配属を考え始めるようになっていた。小職なりに「未来の薬」について思案してみたものの、キックサーブやトップスピントブに関する知識では薬学に関するアイデアが思い浮かぶはずもなかった。小職なりに行き詰まりを感じていた矢先、恩師の生物薬剤学の講義の中で、「細胞製剤」という言葉を聞き、全身から鳥肌が立つような感動を覚えた。恩師は講義の中で、「自分の置かれた「場所」と「時間」に適合しつつ恒常性を維持している細胞が究極の剤形であること、この細胞から学ぶことにより必要な時に、必要な場所に、必要な量だけ薬を運ぶDDS技術の開発が可能になること」を熱く語られていた。大学院から恩師の研究室に入り、「細胞製剤：細胞を敬い、細胞に学べ」という学

問を徹底的に叩き込まれた。細胞生物学に立脚した薬剤学を志向する研究生活を送る中で、同じサイトカインの刺激であっても細胞によって細胞内シグナル伝達経路が異なり、その結果として刺激に対して相反する反応が惹起される場合もあることを知り、細胞によって顔ばかりでなく細胞内も異なることに非常に興味を惹かれた。その当時の私の知識では、当時の薬剤学は細胞表面の議論に終始しているように思え（後に単なる勉強不足であることが分かったが）、『1) 細胞内の物質輸送の様子を見る、2) 細胞の時間（細胞周期）を学ぶ、3) 細胞内でのシグナル伝達の様子を見る』という3点について基礎力を身に付けた上で最終的に『独自の細胞製剤を開発する』という戦略を立て、博士課程在学中に理化学研究所抗生物質研究室に国内留学し、細胞周期阻害剤に関する研究に従事した。その後、徳島文理大学薬学部において、重金属や酸化的ストレスに対する生体応答反応に関する研究に携わり分子・細胞・個体レベルでの研究実施方法に関する基礎を多くの研究者からご教示頂き、同年代の研究者と「研究のオリジナリティーとは？」というテーマを肴に酒席において口泡を飛ばす議論を繰り返した。このときの議論仲間は、医学部、農学部、理学部、工学部など研究文化の異なるモザイク集団であった。振り返ると、この議論が小職の研究哲学をある程度形づくっていたように思う。

そして2002年4月に昭和薬科大学薬剤学教室に移動になったのを機に、独自の創薬研究領域の立ち上げに着手することを決意した。

*平成10年徳島文理大学薬学部助手、平成14年昭和薬科大学講師、平成18年大阪大学大学院薬学研究科助教授を経て平成19年4月より同大学准教授。研究テーマ：生体バリアを利用した創薬研究。趣味：テニス、ジョギング、散歩。連絡先：〒565-0871 吹田市山田丘1-6 E-mail: masuo@phs.osaka-u.ac.jp

2. これまで

独自の創薬研究領域の立ち上げを決意した時に思い浮かんだ言葉が、「細胞を敬え、細胞を学べ」という恩師の教えであった。小職がこの世界に飛び込むきっかけとなったこの言葉を念頭に置き、まず「どの細胞から学ぶか？」ということ考え、①創薬研究において重要な細胞であること、②創薬研究領域において未開拓の分野が残されていること、③活用する細胞生物学的知見が国産であること、④温故知新という基本方針を設定した上で、細胞生物学の教科書を紐解き、上皮細胞に注目することにした。

周知のように上皮細胞は生体内外・組織内外を隔てるバリアとして機能していること、悪性腫瘍の90%が上皮由来であること、多くの病原性微生物の侵入門戸となっていることから、上皮細胞は薬物吸収、癌治療や感染症治療・予防における創薬ターゲットとして有用な性質を有している。上皮細胞を標的とした創薬研究としては、80年代より吸収促進剤が研究開発されているものの、実用化された吸収促進剤はカプリン酸ナトリウムのみであり、非特異的な物質の流入に起因する安全性確保が困難であることから paracellular route を介した薬物吸収促進法の限界が指摘されている部分もあった。上皮細胞生物学の分野では、既に60年代には tight junction (TJ) によって paracellular route がシールされていることが知られていたが、TJ分子基盤の解明は遅れており、ようやく98年になって TJ シールが膜蛋白質によって構成されていることが証明された。このことは、従来の吸収促進剤の限界は paracellular route を利用した創薬研究の限界を示しているのではなく、上皮細胞生物学の遅延により TJ の分子基盤に立脚した創薬戦略が取られてこなかったことに起因していることを意味していた。そこで小職のグループでは、TJ の分子基盤に立脚した創薬研究領域の開拓を広義の目標として設定し、TJ シールの機能本体でありシール機能に組織特異性を有する分子という条件により標的分子の絞り込みを試み、京大月田グループにより同定されていた claudin に注目した。

Claudin は分子量~23 kDa の4回膜貫通蛋白質であり、24種類の分子からなるファミリーを形成している。興味深いことに発現およびバリア機能には

組織特異性が認められ、claudin-1 は皮膚バリア、claudin-5 は血液脳関門バリアを担っている。さらに、ヒトでは12種類の癌において発現異常が認められること、粘膜免疫組織に高発現していること、ウイルスの感染受容体としても機能していることから、claudin を標的とした薬物吸収促進法、癌ターゲティング法、粘膜ワクチン、抗ウイルス薬の開発など、新たな創薬研究領域創成の可能性が強く示唆された。しかしながら、claudin は抗原性が低い上に立体構造が解析されておらず、抗体を含めて claudin binder の創製は著しく立ち遅れており、claudin を利用した創薬研究は皆無に等しいのが現状であった。

ウエルシュ菌下痢毒素 (CPE) はヒトの食中毒を引き起こすことから細菌学の分野で詳細な解析が進められており、97年にCPE受容体が同定されていたものの、本受容体の生理的役割についての解析は遅々として進展していなかった。99年月田グループにより、CPE受容体が claudin-4 であること、CPEの受容体結合領域断片 (C-CPE) が細胞傷害性を伴うことなく claudin-4 に結合し claudin-4 バリア機能を阻害することが報告され、claudin が TJ バリア機能を担っていることが実験的に初めて証明されていた。小職は、徳島文理大在職中にウエルシュ菌研究の世界的権威である櫻井純先生から、細菌毒素の持つ特異性について薫陶を受けていたこともあり、この月田グループの報告を読んだ時に C-CPE を利用することで claudin を標的とした創薬研究を展開できると直感した。さらに、C-CPE はポリペプチドであり将来的な遺伝子工学的手法を用いた改変が容易 (C-CPE を prototype として用いた新規 claudin binder の創製が可能) であることから、C-CPE を claudin binder のモデル分子として利用し、claudin を利用した創薬研究に着手することにした。


2002年7月に、C-CPEの遺伝子を持っている阪大微研堀口先生に手紙を差し上げ、C-CPE cDNA を譲渡して頂き、試行錯誤しながら C-CPE 蛋白質を作製した。そして、当時修士1年生であった浅野長祥君にお願いし、モデル薬物として分子量4000のデキストラン (FD-4) を用いてラット腸管ループ法により粘膜吸収促進活性を解析してもらった。すると、わずか0.2 mg/ml の処理で劇的なFD-4の吸収促進活性が観察され、このとき粘膜傷害性は観察さ

れなかった。当時小職は天然物由来の生理活性物質の機能解析および胎盤における亜鉛代謝に関する研究を進めており、claudin を利用した研究はエフォートの10%程度を割いているに過ぎない状況であった。実際、生理活性物質の機能解析については論文1報がアクセプトされ、複数の論文を投稿準備中という状況であり、両研究とも順調に推移していた。そこで、主に下級生を中心にテーマの選択と集中に関して忌憚りの無いディスカッションを行い、両研究テーマを切り上げ claudin を利用した創薬研究にチームを挙げて取り組むことを決意した。そして、C-CPE が唯一の claudin binder であることを踏まえ、① C-CPE を claudin binder のモデル分子として利用し、claudin を利用した創薬研究の可能性を検証すること、② C-CPE を prototype として用いた claudin binder 創製系を構築すること、③ 新たな claudin 制御分子の探索を試みることをメインテーマとして

設定し、claudin を利用した創薬研究に本格的にアタックすることにした。2002年12月のことである。

まず、C-CPE の粘膜吸収促進活性が claudin-4 を介して生じていることを確認するために、C-CPE の claudin-4 結合ドメインの同定を試み、C-CPE の claudin-4 結合領域欠損体を創出し、本欠損体を用いて claudin を利用した粘膜吸収促進法の有用性を明らかにした(図1)¹⁾。さらに、C-CPE 変異体を用いて claudin を利用したペプチド医薬の経肺・経鼻吸収促進法を開発した²⁾。また、C-CPE と緑膿菌エキソトキシン由来の蛋白合成阻害因子(PSIF)との融合蛋白質 C-CPE-PSIF を作製し、claudin-4 発現癌細胞に対する抗腫瘍活性を解析し、C-CPE-PSIF が claudin-4 指向性分子であること、C-CPE-PSIF が *in vitro* および *in vivo* で抗腫瘍活性を有することを見出し、C-CPE を用いた痛ターゲットング法を確立した(図2)^{3,4)}。さらに、2003年に東大医科研の清野グループにより、粘膜免疫組織に claudin-4 が高発現していることが見出され、claudin-4 を標的とした粘膜免疫組織への抗原デリバリーの可能性が示唆されていた。そこで、C-CPE とモデル抗原の融合蛋白質を作製し、claudin-4 を標的とした粘膜ワクチン創製の可否を検証し、C-CPE とモデル抗原との混合液投与では抗原特異的な免疫応答が観察され

A. 血漿中FD-4濃度の経時変化



B. AUC値




図1 C-CPE の腸管吸収促進活性

FITC ラベルした分子量 4000 のデキストラン (FD-4) をモデル薬物として用いて、ラット腸管ループ法により C-CPE の吸収促進活性を解析(文献 1 を一部改変)。

A. C-CPE-PSIF



B. Claudin (CL) 特異性




図2 Claudin-4 指向性分子

Pseudomonas aeruginosa exotoxin の蛋白質合成阻害ドメイン (PSIF) と C-CPE との融合体 (A) を作製し、各種 claudin 発現細胞に各濃度 24 時間処理後に WST アッセイにより細胞毒性を解析 (B)。




図3 Claudin binder を利用した粘膜ワクチン
 モデル抗原 (卵白アルブミン: OVA) と C-CPE との融合体 (A) を作製し, マウスに経鼻投与し, 血中 (B), 鼻粘膜洗浄液 (C), 糞便抽出液 (D) に含まれる OVA 特異的抗体価を解析.




図4 生体バリアを利用した創薬研究

ないこと, 融合蛋白質投与によって投与粘膜面のみならず遠隔粘膜面での抗原特異的 IgA 産生が起きること, claudin-4 結合性が消失した C-CPE 変異体との融合蛋白質では抗体価の上昇が観察されないことを見出し, claudin-4 を標的とした粘膜ワクチン技術を初めて確立した (図3)⁵⁾. さらに, C-CPE を prototype として用いた claudin binder 創製を図るために5年余りの歳月をかけて, C-CPE の claudin 結合残基を網羅的に解析, claudin binder のスクリーニングシステムを構築し, 最近新規 claudin binder の取得に成功した (Unpublished data).

以上, 現在までの検討により, claudin を標的と

した粘膜吸収促進法, 痛ターゲティング法, 粘膜ワクチン技術を創製し, claudin を利用した創薬の可能性を先駆けて報告してきた. さらに, C-CPE に比して優れた粘膜バリア制御活性を有する新規 claudin binder の創製, および claudin binder 創製系の構築にも成功している.

3. これから

上述したように, 現在までに claudin が創薬ターゲットとして多くの可能性を秘めていることを見出してきた. Claudin は 24 種類の分子が多様な組み合わせによって様々な性質を有する TJ シールを構成し, 生体内の多種多様な内部環境を維持していることから, この内部環境維持機構を自由自在に制御することができれば, 新たな drug delivery system (DDS) の開発に繋がる可能性がある. 今後は, 独自の claudin binder 創製技術を駆使して, 多種多様な結合域を有する claudin binder を創製し, 組織特異性および透過物質特異性を併せ持つ新規薬物吸収促進法の開発, 新規癌ターゲティング法, ウイルス感染阻害剤の開発などの創薬研究を展開していきたい (図4).

三つ子の魂百までというように, 「細胞を敬え, 細